Hybrid biomaterial hydrogel loading iRGD&PS double modified lipid nanoparticles ameliorates diabetic wound healing through promoting efferocytosis and glycolysis-related macrophage reprogramming
• ABPP and molecular docking revealed the anti-inflammatory mechanism of tiliroside. • Gel@Til iRGD&PS@PLGA NPs enabled pH-responsive release and macrophage-targeted delivery in the inflammatory microenvironment. • The mechanism of improved wound healing by Gel@Til iRGD&PS@PLGA NPs was revealed. Efferocytosis is a critical process whereby macrophages residing in the wound area play a key role in the efficient clearing and degradation of apoptotic neutrophils. This process is followed by a phenotypic transition toward an anti-inflammatory state, essential for inflammation resolution and tissue repair. The cystine/glutamate antiporter SLC7A11 has recently been identified as an inhibitor of efferocytosis, and its blockade has been found to enhance wound healing. In this study, we demonstrated that tiliroside, a plant-derived glycoside containing flavones, binds directly to SLC7A11 and pyruvate kinase isozyme M2 (PKM2). This was established by molecular docking predictions and activity-based protein profiling (ABPP). Cytological experiments revealed that tiliroside promoted the process of efferocytosis and led to glycolysis-related macrophage reprogramming. To facilitate targeted drug delivery to macrophages at diabetic wound sites, we designed a novel hybrid biomaterial. This hybrid biomaterial, prepared as Gel@Til iRGD&PS@PLGA NPs is manufactured by loading tiliroside (Til)-conjugated iRGD&PS double modified lipid nanoparticles (iRGD&PS@PLGA NPs) into a pH-responsive hydrogel matrix. The administration of Gel@Til iRGD&PS@PLGA NPs in diabetic cutaneous wound models has been shown to significantly promote tissue regeneration through the promotion of efferocytosis and glycolysis-related macrophage reprogramming. Therefore, this study introduces a novel approach to diabetic wound management by leveraging the promotion of efferocytosis.
Authors
- Weixian Hu (ORCID: https://orcid.org/0000-0002-3792-4819)
- Qian Feng
- Yuval Rinkevich (ORCID: https://orcid.org/0000-0003-3658-0257)
- Michael G. Alfertshofer (ORCID: https://orcid.org/0000-0002-4892-2376)
- Kangkang Zha (ORCID: https://orcid.org/0000-0003-0421-5466)
- Samuel A. Knoedler (ORCID: https://orcid.org/0000-0001-5798-8003)
- Bong‐Sung Kim (ORCID: https://orcid.org/0000-0002-0493-3196)
- Adriana C. Panayi (ORCID: https://orcid.org/0000-0003-4053-9855)
- Bobin Mi (ORCID: https://orcid.org/0000-0002-6994-4363)
- Hui Li (ORCID: https://orcid.org/0000-0002-5740-2655)
- Guohui Liu (ORCID: https://orcid.org/0000-0002-2013-1396)
- Wenqian Zhang
- Shengming Zhang (ORCID: https://orcid.org/0009-0004-0603-3601)
- Yanzhi Zhao (ORCID: https://orcid.org/0009-0007-8362-1564)
- Wenhao Han
Institutions
- Brigham and Women's Hospital (US)
- Union Hospital (HK)
- Harvard University (US)
- Chongqing University (CN)
- Heidelberg University (DE)
- Ludwigshafen University of Business and Society (DE)
- TUM Klinikum (DE)
- Helmholtz Zentrum München (DE)
- Wuhan University (CN)
- University Hospital of Zurich (CH)
- Hubei Zhongshan Hospital (CN)
- Huazhong University of Science and Technology (CN)
- Technical University of Munich (DE)
Publication Details
- Journal
- Chemical Engineering Journal
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.cej.2024.154800
- Citations
- 3
- Primary Topic
- Wound Healing and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.75
Funders
- National Natural Science Foundation of China
- Wuhan University of Science and Technology
- Science and Technology Innovation as a Whole Plan Projects of Shaanxi Province
- National Natural Science Foundation of China-Yunnan Joint Fund